KTTA Pasithea Therapeutics Corp. Insider Trading

10% owner Coastlands Capital LP buys 100,000 shares of KTTA at $0.53; stock down 74.8% from 52-week high amid unprofitability.

Coastlands Capital LP, a 10% shareholder, purchased 100,000 shares at $0.53 on 2026-06-17, expanding its position from 3,735,035 to 3,835,035 shares. The transaction occurred as KTTA trades at $0.52, down 74.8% from its 52-week high of $2.06 and down 25.7% over the prior 30 days. The company is unprofitable with a net income of $-2.9M against quarterly revenue of only $218.6K, and a market cap of $17.4M. This buy-in from an existing 10% owner during sharply depressed trading and sustained loss-making conditions merits monitoring, as it may indicate near-term confidence in a turnaround, though the absence of material operational improvements or guidance changes in the filing limits the evidentiary weight of this single transaction.

Director Dumesnil Simon bought 33,333 shares of KTTA at $0.75; holdings increase +1333.3%; 2 other insiders also bought within 14 days.

Dumesnil Simon, a director, purchased 33,333 shares at $0.75 on 2025-11-28, increasing his holdings from 2,500 shares to 35,833 shares—a gain of +1333.3% relative to his pre-transaction position. This transaction co-occurs with a cluster pattern: 2 other insiders also bought within the past 14 days. The context reveals material volatility and fundamental weakness: the stock is -63.2% from its 52-week high of $3.15, though it has recovered +42.6% over the past 30 days and +29.1% over 90 days. Pasithea Therapeutics remains unprofitable, with a net loss of $-3,037,420.00 in its most recent full fiscal year and quarterly revenue of only $218,608.00, while the company carries a market cap of $8,634,549.32. The convergence of multiple insider purchases at depressed valuations within a short window, alongside signs of recent price recovery, warrants examination of whether this reflects deliberate positioning by the board or merely coincidental timing around company developments.

CEO Marques Tiago bought 33,333 shares at $0.75 (Nov 28); cluster buy pattern with 2 other insiders in past 14 days

Marques Tiago, Chief Executive Officer, purchased 33,333 shares at $0.75, increasing his holdings by +83.3% from 40,001 to 73,334 shares. This purchase coincides with a cluster pattern: 2 other insiders also bought within the past 14 days. The company shows strong revenue growth of +3130.4% (annual), yet remains unprofitable with net income of $-3,037,420.00 over its most recent full fiscal year and $-3.0M in the latest quarter. At the transaction price of $0.75, the stock has since recovered to $1.16 (+42.6% over 30 days, +29.1% over 90 days) but remains -63.2% from its 52-week high of $3.15, suggesting the purchase was made during a down period relative to recent peak. The coordinated buying activity by multiple insiders warrants examination of whether material information or strategic developments underpin these acquisitions, particularly given the company's unprofitable status and elevated recent volatility.

Director STEINMAN LAWRENCE purchases 133,333 shares of KTTA at $0.75 (+200.9% vs prior holdings); cross-ticker track record shows 100% 90d win rate.

Director STEINMAN LAWRENCE purchased 133,333 shares at $0.75, more than doubling his holdings from 66,358 to 199,691 shares. His cross-ticker track record reveals exceptionally strong prior performance: an average 90-day return of +3068.6% with a 100% win rate across 3 prior buys, and at KTTA specifically, a prior 2023 buy returned +2709.7% over 90 days—both clearly well-timed entries. The current stock price of $1.16 is -63.2% from its 52-week high of $3.15, suggesting a depressed entry point relative to recent ranges. A cluster pattern shows 2 other insiders also bought within 14 days, indicating coordinated board-level accumulation. However, the company's fundamentals reveal structural challenges: unprofitable with a negative full-year net income of $-3,037,420.00 against only $218,608.00 in latest quarterly revenue, though annual revenue growth of +3130.4% suggests an early-stage trajectory. The tension between strong insider track record and negative profitability metrics warrants scrutiny of whether this reflects a high-conviction accumulation at a trough or execution risk in a loss-making operation.